| Literature DB >> 31000919 |
Swatantra Nagendra Rao1, Nikhil Khattar2, Arif Akhtar1, Hemant Goel1, Anuj Varshney1, Rajeev Sood1.
Abstract
INTRODUCTION: Oral mucosal graft (OMG) is the gold standard for urethral substitution but has poor results in long anterior urethral strictures and chronic tobacco-exposed oral mucosa. Saphenous vein has been recently described for long-segment anterior urethral stricture with successful initial results. Our objective was to compare the early outcomes of everted saphenous vein graft (eSVG) substitution urethroplasty in patients with tobacco-exposed oral mucosa and OMG urethroplasty in patients with nontobacco-exposed oral mucosa for long anterior urethral strictures.Entities:
Year: 2019 PMID: 31000919 PMCID: PMC6458808 DOI: 10.4103/iju.IJU_352_18
Source DB: PubMed Journal: Indian J Urol ISSN: 0970-1591
Figure 1(a) Course of saphenous vein premarked with color Doppler with planned sites of incisions (b) Vein dissected at the saphenofemoral junction. Any tributaries are tied and divided (not divided by energy sources) to facilitate further hydrodistention (c) The vein is divided cranially and tunneled into caudal incisions depending on the length required
Figure 2(a) Long segment of the saphenous vein is retrieved through three island incisions and is ready to be divided. All tributaries are ligated. The penis has been inverted into the perineum, urethra dissected on one side and opened dorsally, (b) the vein is hydrodistended, and (c) the vein is then opened all along its length to be used as graft with endothelium kept on the outside
Figure 3The vein has been placed as a dorsal graft and has been sutured to one edge of the strictured urethra
Demography and preoperative characteristics of patients in both the groups
| Variables | Group 1 (OMG) ( | Group 2 (eSVG) | ||||
|---|---|---|---|---|---|---|
| Mean | Range | Mean | Range | |||
| Age (years) | 37.6±17 | 16-76 | 46.73±15.82 | 20-66 | 0.949 | |
| Duration of symptoms (years) | 5.63±4.9 | 1-20 | 5.43±5.81 | 1-25 | 0.769 | |
| Serum creatinine | 0.84±0.28 | 0.5-1.6 | 0.96±0.36 | 0.7-2.1 | 0.171 | |
| IPSS | 24±2.83 | 20-28 | 24.91±2.43 | 20-28 | 0.646 | |
| QOL measurement | 5.67±0.62 | 4-6 | 5.6±0.63 | 4-6 | 0.718 | |
| Qmax (ml/s) | 6.44±3.37 ( | 2.5-13.3 | 7.22±3.21 ( | 2.9-12.5 | 0.797 | |
| PVR (ml) | 100.56±83.01 | 15-260 | 82.18±69.21 | 10-230 | 0.879 | |
| Narrow meatus ( | 3 | 4 | 1.00 | |||
| Previous dilatation ( | 5 | 5 | 0.435 | |||
| Previous DVIU ( | 4 | 4 | 0.766 | |||
| History of catheterization ( | 12 | 11 | 1.000 | |||
| Urethral discharge ( | 5 | 5 | 1.000 | |||
| Trauma ( | 2 | 0 | 0.483 | |||
OMG: Oral mucosal graft, eSVG: Everted saphenous vein graft, PVR: Postvoided residual urine, DVIU: Direct vision internal urethrotomy, SPC: Suprapubic Cystosctomy, IPSS: International Prostate Symptom Score , QOL: Quality of life
Intraoperative details
| Variables | Group 1 (OMG) | Group 2 (eSVG) | |||||
|---|---|---|---|---|---|---|---|
| Maximum | Minimum | Mean±SD | Maximum | Minimum | Mean±SD | ||
| Length of stricture (cm) | 18 | 6 | 10.8±3.21 | 18 | 9 | 13.6±2.59 | 0.015 |
| Caliber of urethra in stricture segment (Fr) | 10 | 6 | 6.8±1.26 | 8 | 6 | 6.8±1.01 | 0.825 |
| Length of graft harvested (cm) | 19 | 7 | 12.33±3.31 | 20 | 11 | 15.73±2.6 | 0.007 |
| Operative time (min) | 210 | 150 | 192±18.21 | 240 | 150 | 194.6±21.34 | 0.697 |
| Graft harvesting time (min) | 40 | 32 | 35.73±2.58 | 40 | 30 | 35.67±2.85 | 0.340 |
OMG: Oral mucosal graft, eSVG: Everted saphenous vein graft, SD: Standard deviation
Postoperative details
| Variables | Group 1 (OMG) | Group 2 (eSVG) | |||
|---|---|---|---|---|---|
| Mean | Range | Mean | Range | ||
| At 1 month ( | 15 | 15 | |||
| IPSS | 7.87±0.99 | 7-10 | 8.87±2 | 7-14 | 0.119 |
| QOL | 1.33±0.49 | 1-2 | 1.53±0.74 | 1-3 | 0.541 |
| Qmax (ml/s) | 25.33±5.09 | 18.5-34.4 | 22.11±5.19 | 12.2-28.8 | 0.940 |
| PVR | 29.87±20 | 10-78 | 30.07±19.26 | 10-85 | 0.933 |
| At 3 month ( | 15 | 15 | |||
| IPSS | 9.07±2.96 | 7-18 | 10.13±4.55 | 7-22 | 0.378 |
| QOL | 1.67±0.72 | 1-3 | 1.87±0.99 | 1-4 | 0.700 |
| Qmax | 22.63±7.18 | 12.2-36.6 | 19.65±5.72 | 7.8-28.8 | 0.345 |
| PVR | 40.47±36.7 | 10-150 | 45.0±28.92 | 10-110 | 0.212 |
| At 6 month ( | 12 (3 failure) | 13 (2 failure) | |||
| IPSS | 8.33±1.97 | 7-14 | 8.62±1.45 | 7-12 | 0.68 |
| QOL | 1.5±0.67 | 1-3 | 1.61±0.65 | 1-3 | 0.68 |
| Qmax | 24.80±5.62 | 16.2-32.6 | 21.32±3.22 | 16.4-27.2 | 0.07 |
| PVR | 26.50±11.61 | 10-50 | 27.92±10.95 | 15-60 | 0.76 |
| At 12 months ( | 12 (3 failure) | 13 (2 failure) | |||
| IPSS | 8.75±3.02 | 7-18 | 8.76±2.86 | 7-18 | 0.99 |
| QOL | 1.83±0.72 | 1-3 | 1.53±0.88 | 1-4 | 0.36 |
| Qmax | 23.90±4.66 | 13.4-29.4 | 22.6±4.25 | 12.4-28.4 | 0.47 |
| PVR | 25.5±13.56 | 10-60 | 29.23±13.82 | 20-70 | 0.50 |
| At 18 months ( | 9 (2 patients lost to follow-up and 4 failures) | 11 (1 patient lost to follow-up and 3 failures) | |||
| IPSS | 7.88±0.93 | 7-10 | 8.0±0.77 | 7-10 | 0.75 |
| QOL | 1.44±0.53 | 1-2 | 1.36±0.49 | 1-2 | 0.73 |
| Qmax | 25.69±3.30 | 20.8-30.6 | 22.65±3.35 | 17.8-28.2 | 0.06 |
| PVR | 20.44±6.77 | 10-30 | 24.53±6.88 | 15-35 | 0.20 |
n: Number of patients, OMG: Oral mucosal graft, eSVG: Everted saphenous vein graft, PVR: Postvoided residual urine, IPSS: International Prostate Symptom Score , QOL: Quality of life